Table 2.

Patient characteristics and doses given in each subject, cohort, and cycle

Cohort	Subject number	Sex/age	WHO diagnosis	Donor	GVHD gradea		Cycle (mg/m2/day for 5 days)
					Acute	Chronic	1	2	3	4
1	1	F/19	RAEB-2	MSD	0	0	5b,c	1.5	1.5	1.5
	2	M/36	AML	MSD	0	0	5b	6	5.5	6
	3	M/60	RAEB-2	MUD	1	0	5	–	–	–
	4	M/48	AML	MSD	0	0	5b,c	1.5	2.5	3
2	5	M/64	RAEB-2	PMUD	1	0	4b	4	5.5	7
	6	F/43	RAEB-2	MSD	0	0	4b	7	8	12
	7	M/64	AML	MSD	0	0	4b	6	5.5	5.5
3	8	F/51	RAEB-2	MUD	1	0	5b	7.5b,c	7.5c	7
	9	F/59	RAEB-1	MUD	2	0	5b,c	3.5	4	4.5
	10	F/36	RAEB-2	MUD	1	0	5b	6b	8.5	9
4	11	M/64	RAEB-2	MSD	2	0	5.5b	2b	–	–
	12	M/60	RAEB-2	MSD	0	Mild	5.5b,c	4.5b	7	8
	13	M/41	RAEB-2	MSD	0	0	5.5b,c	3	5	8
5	14	M/49	AML	MUD	2	0	5b	1.5	2.5	3
	15	F/50	AML	MSD	2	0	5b,c	4	6	9
	16	F/49	RAEB-2	MSD	2	0	5b	7.5	8	11c

GVHD graft-versus-host disease, RAEB refractory anemia with excess blast, MSD matched sibling donor, PMUD partially matched unrelated donor, MUD matched unrelated donor

^aAssessed at the time of decitabine initiation

^bIndividual dose titration (IDT) by the PK-PD model was not applied

^cThe cycles where grade 4 toxicities occurred